FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells
Resistance to CDK4/6 inhibitors (CDKis) is emerging as a clinical challenge. Identification of the factors contributing to CDKi resistance, with mechanistic insight, is of pivotal significance. Recent studies linked aberrant FGFR signaling to CDKi resistance. However, detailed mechanisms are less cl...
Guardado en:
Autores principales: | Qiong Cheng, Zhikun Ma, Yujie Shi, Amanda B. Parris, Lingfei Kong, Xiaohe Yang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/38f749d3ca5843bd8db0c6c7fa6acc84 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Biological Significance and Targeting of the FGFR Axis in Cancer
por: Athina-Myrto Chioni, et al.
Publicado: (2021) -
Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer
por: R.K. Ismail, et al.
Publicado: (2021) -
Profile of palbociclib in the treatment of metastatic breast cancer
por: Ehab M, et al.
Publicado: (2016) -
FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance
por: Jakub Szymczyk, et al.
Publicado: (2021) -
Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
por: Erin R. Scheidemann, et al.
Publicado: (2021)